Baltimore, MD (February 14, 2014) – BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that the company has achieved CE/IVD marking for the BD OnclarityTM HPV Assay on the new BD ViperTM LT System.
The BD Onclarity HPV Assay targets E6/E7 DNA oncogenes and is designed to provide physicians access to broader High Risk (HR) HPV genotype information beyond types 16 and 18 to guide informed treatment decisions for their patients. The BD Onclarity HPV Assay reports results on six discrete HR HPV genotypes (16, 18, 31, 45, 51 and 52) with the remaining eight high-risk genotypes reported in three small groups: (33, 58), (35, 39, 68) and (56, 59, 66). Individual and grouped HR HPV genotype results are obtained from the same sample with no additional processing steps required.
“Cervical cancer continues to be a major health issue around the world and poses a significant threat to women’s health. The launch of our new platform and assay offers physicians a more complete assessment of a patient’s risk,” said Paul Holt, Global Business Leader, Women’s Health and Cancer, BD Diagnostics – Diagnostic Systems. “It is now clear that high-risk HPV genotypes differ in their ability to persist and lead to cervical cancer. The BD Onclarity HPV Assay screens for all 14 high-risk types and provides access to genotype information that is relevant to a patient’s risk for development of precursors to cervical cancer.”
The BD Onclarity HPV Assay was recently clinically evaluated according to International Guidelines for clinical HPV assay performance and met all acceptance criteria.1 The study was conducted in three leading HPV laboratories in London, Copenhagen and Edinburgh, and compared the performance of the BD Onclarity HPV Assay to a clinically validated reference standard. The independent study also demonstrated excellent inter- and intra-laboratory assay reproducibility in the respective laboratories.
The BD Viper LT System is a bench-top molecular platform that automates sample processing, nucleic acid extraction, Real-Time Polymerase Chain Reaction (RT-PCR) amplification and detection and result reporting with minimal user intervention. The BD Viper LT system is designed to manage sample tubes with pierceable caps and ready to use reagents. The “load and go” capability and ease of use design of the BD Viper LT system delivers true walkaway potential that maximizes laboratory productivity.
The combination of the BD Viper LT system with the BD Onclarity HPV Assay brings to pathology and molecular labs an innovative solution that enhances clinical utility, increases flexibility and improves laboratory efficiency.
Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV).2 Although there are more than 100 HPV genotypes, 14 HR genotypes are considered to be cancer-causing.3 Many women with a positive HR HPV result will clear the infection on their own before it progresses towards cervical cancer.4
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
1. Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J., Bonde J , J Med Microb Diagn Forthcoming 2014.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. 1999. The Journal of pathology 189:12-19
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. 2003. The New England journal of medicine 348:518-27
4. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, et al. 2012. Vaccine 30 Suppl 5:F24-33